Company
Celgene Corporation
NASDAQ:CELG
Celgene Corporation is an integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
44 stories · page 1 of 3
Frontier IP sees maturity spread across portfolio companies
The investment firm focuses on providing consultancy services to universities and other research organisations to help them commercialise any intellectual property arising from their research
Investments and investor services
LATE MOVERS: Bed Bath & Beyond stock spikes as activists move to scrub its board
Also making moves were Apple, Boeing, Carnival and merging drugmakers Bristol-Myers and Celgene
Frontier IP upgrades full year forecasts as portfolio firm Exscientia inks deal with biotech giant Celgene
The collaboration included an initial upfront payment of US$25mln for Exscientia in addition to “substantial milestones” and tiered royalties on net sales of any product developed
Archive
Proactive news snapshot: ValiRx, LoopUp Group, Kibo Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
LATE MOVERS: Tesla shares slip after news of $35,000 Model 3’s launch
Also on the move are Booking Holdings, Box Inc, Bristol-Myers Squibb, Celgene, Gap, HP and Nordstrom
MORNING MOVERS: Celgene crashes as Bristol-Myers takeover thrown into doubt
Also in play in are Square Inc, Box Inc and HP Inc
Archive
EARLY MOVERS: Celgene crashes in pre-market as Bristol-Myers takeover thrown into doubt
Also in play in pre-market deals New York is Square Inc and Box Inc
Archive
EARLY MOVERS: Celgene crashes in pre-market as Bristol-Myers takeover thrown into doubt
Also in play in pre-market deals New York is Square Inc and Box Inc
Eli Lilly’s $8B bet on Loxo is a ‘vote of confidence’ for novel scientific approaches that use DNA to treat cancer
Genprex Inc CEO Rodney Varner said the deal was ‘further validation’ of the promise of cancer therapies that target specific cancer-causing genetic abnormalities
Archive
EARLY MOVERS - Loxo Oncology shares skyrocket on news of Eli Lilly acquisition; DXC Technology to buy Luxoft Holding
Also in the frame in pre-market is electric car titan Tesla and media group CBS Corp
Biotech CEOs see Bristol-Myers' $74B acquisition of Celgene as a win
The tie-up underlines how the largest pharmaceutical companies are eager to embark on the acquisition trail to boost pipelines
Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal
The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches
EARLY MOVERS: Celgene rallies as Bristol-Myers offers to buy cancer drug company
Airline stocks decline after Delta lowered its outlook for revenue growth
Celgene and Accleron see positive results on joint blood disorder drug
The Phase 3 double-blind study found that the drug was able to lower the rate of transfusions needed
World Wrestling Entertainment shares bout higher along with Micron Technology before the bell
Kohl's Corp and the New York Stock Exchange are also in focus before the bell
Celgene rises on 1Q beat, updated full-year guidance
CEO says 'strong global demand and excellent commercial execution' drove results
Celgene slumps as US FDA rejects filing for key multiple sclerosis drug
The company received a ‘refusal to file’ letter from FDA for its ozanimod drug
Celgene Corp, Etsy Inc, Axon Enterprise Inc and more - AFTER HOURS
A look at what moved the dial after hours in New York trade
Could Sorrento Therapeutics be the next minnow gobbled up in biotech feeding frenzy?
A leading small-cap broker reckons Juno stock is worth US$30 - the shares are currently changing hands for around US$7